Survival outcomes (mPFS 8.2 months; 12-month OS 80.8%) compare favorably with typical first-line chemo-immunotherapy ...

Frontline gastric/GE junction cancer care now pairs chemo with checkpoint inhibitors for PD-L1 CPS≥1, improving survival and ...

Regulatory review timelines shifted from March 29 to June 29, 2026, after FDA requested more time to assess CMC/manufacturing ...

In patients with marginal zone lymphoma (MZL), venetoclax (Venclexta) plus ibrutinib (Imbruvica) demonstrated safety and ...

Week-18 ORR equivalence was achieved for HD204 vs reference bevacizumab (48.7% vs 46.5%), with both risk ratio and risk ...

Theriva Biologics has received FDA agreement on the core design elements of a pivotal Phase 3 trial evaluating zabilugene ...

Nadofaragene firadenovec-vncg is the only FDA-approved nonreplicating intravesical gene therapy for high-risk ...

The FDA has approved relacorilant (Lifyorli) in combination with nab-paclitaxel for the treatment of patients with ...

Discover how CAR-T, bispecifics and gene therapy reshape cancer care—and what clinics need for safe, reimbursable outpatient ...

With thoracic oncology in the middle of a combinatorial revolution—EGFR-targeted doublets and triplets, a maturing ...

In an interview with Targeted Oncology, David Sallman, MD, of Moffitt Cancer Center, addresses the nuanced decision-making ...

For decades, 7+3—consisting of cytarabine plus an anthracycline—has been the backbone of induction therapy for fit adults ...